Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have been used for different histologic types of cancer including...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wei, Zhao, Yunfeng, Du, He, Guo, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416501/
https://www.ncbi.nlm.nih.gov/pubmed/34490104
http://dx.doi.org/10.3389/fonc.2021.704336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416501/
https://www.ncbi.nlm.nih.gov/pubmed/34490104
http://dx.doi.org/10.3389/fonc.2021.704336

Ejemplares similares